UNIGE document Scientific Article
previous document  unige:7088  next document
add to browser collection

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy

Arnedo, Mireia
Furrer, Hansjakob
Elzi, Luigia
Weber, Rainer
Vernazza, Pietro
show hidden authors show all authors [1 - 14]
Published in Pharmacogenetics and genomics. 2007, vol. 17, no. 9, p. 755-764
Abstract BACKGROUND: HIV-1 infected individuals have an increased cardiovascular risk which is partially mediated by dyslipidemia. Single nucleotide polymorphisms in multiple genes involved in lipid transport and metabolism are presumed to modulate the risk of dyslipidemia in response to antiretroviral therapy. METHODS: The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years. An exploratory genetic score was tested that takes into account the cumulative contribution of multiple gene variants to plasma lipids. RESULTS: Variants of ABCA1, APOA5, APOC3, APOE, and CETP contributed to plasma triglyceride levels, particularly in the setting of ritonavir-containing antiretroviral therapy. Variants of APOA5 and CETP contributed to high-density lipoprotein-cholesterol levels. Variants of CETP and LIPG contributed to non-high-density lipoprotein-cholesterol levels, a finding not reported previously. Sustained hypertriglyceridemia and low high-density lipoprotein-cholesterol during the study period was significantly associated with the genetic score. CONCLUSIONS: Single nucleotide polymorphisms of ABCA1, APOA5, APOC3, APOE, and CETP contribute to plasma triglyceride and high-density lipoprotein-cholesterol levels during antiretroviral therapy exposure. Genetic profiling may contribute to the identification of patients at risk for antiretroviral therapy-related dyslipidemia.
Keywords ATP-Binding Cassette Transporters/geneticsAdultAnti-HIV Agents/ adverse effectsApolipoprotein C-III/geneticsApolipoproteins A/geneticsApolipoproteins E/geneticsCholesterol Ester Transfer Proteins/geneticsCholesterol, HDL/bloodDyslipidemias/blood/ etiology/ geneticsFemaleHIV Infections/blood/complications/drug therapy/geneticsHumansLipids/bloodMaleMiddle AgedModels, BiologicalPharmacogeneticsPolymorphism, Single NucleotideRisk FactorsTriglycerides/blood
PMID: 17700364
Full text
(ISO format)
ARNEDO, Mireia et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. In: Pharmacogenetics and genomics, 2007, vol. 17, n° 9, p. 755-764. doi: 10.1097/FPC.0b013e32814db8b7 https://archive-ouverte.unige.ch/unige:7088

489 hits

0 download


Deposited on : 2010-06-21

Export document
Format :
Citation style :